Landmark debt deal enables commercial readiness for ITM-11, supports pipeline expansion and Actinium-225 manufacturing scale-up

ITM Isotope Technologies Munich SE (ITM), a leader in targeted radiopharmaceuticals, has secured up to $262.5 million in non-dilutive debt financing from Blue Owl Capital, providing a major boost to its US market ambitions and next-generation oncology pipeline.

The funds will primarily support commercial readiness and a potential US launch of the company’s lead candidate, n.c.a. 177Lu-edotreotide (ITM-11), following positive top-line results from the Phase 3 COMPETE trial in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The candidate met its primary endpoint and ITM is now preparing to submit a New Drug Application (NDA) to the US Food and Drug Administration later in 2025.

The deal will see ITM receive $140 million upfront, with additional tranches available under undisclosed terms. It reflects growing investor appetite for scalable precision oncology technologies, particularly those leveraging radioligand therapy, which is gaining traction as a targeted systemic treatment for hard-to-treat tumors.

A platform for expansion

The financing will also support broader goals, including continued development of ITM’s theranostic pipeline, which combines diagnostic imaging and targeted therapy, and the scale-up of Actinium-225 manufacturing through its joint venture Actineer. This is particularly significant given Actinium-225’s promise in alpha-emitting therapies that offer higher potency with reduced off-target toxicity.

CEO Dr Andrew Cavey described the agreement as both strategic and transformative.

“This funding from Blue Owl enables us to move rapidly toward the potential US commercialization of ITM-11, while giving us flexibility to accelerate our innovation pipeline and manufacturing capabilities.”

ITM’s vertically integrated model, which covers radioisotope production, radioligand development and a commercial supply chain, positions the company well in the growing radiopharmaceutical space. Its ability to control both the supply of key isotopes and the development of novel treatments provides strategic advantages in a sector often constrained by availability and logistics.

Growing validation of radiopharmaceuticals

The financing marks one of the largest non-dilutive capital raises in the radiopharma sector this year and highlights increasing recognition of the field’s commercial viability.

Sandip Agarwala, Managing Director and Head of Life Sciences at Blue Owl, said: “With its vertically integrated approach that combines a profitable radioisotope manufacturing business with radiopharmaceutical pipeline development, we believe ITM is uniquely positioned to positively impact the precision oncology sector.”

The deal comes at a time when pharmaceutical companies are ramping up investment in radiopharmaceuticals. Recent years have seen a wave of acquisitions, partnerships and strategic deals. Regulatory approvals of radioligand therapies for prostate and neuroendocrine cancers have validated the approach, although challenges remain in manufacturing scale-up, isotope supply and regulatory alignment.

The road ahead

As ITM prepares to bring ITM-11 to market, the competitive landscape for radioligand therapies is growing. However, with positive late-stage trial results, in-house isotope production capabilities and a substantial financial runway, the company appears well placed for the path ahead.

If approved, ITM-11 could become one of the first targeted radiotherapies for GEP-NETs in the US, addressing a significant unmet need in a disease area where diagnosis is often delayed and treatment options are limited.